paclitaxel

Original Contribution

Outcomes Following Coronary Chronic Total Occlusion Revascularization With Drug-Coated Balloons

02/21/2024

Yuan Zhi , MD;

Vanessa Bade , BSc;

Adrian Attinger-Toller , MD;

Florim Cuculi , MD;

Irena Majcen , PhD;

Mathias Wolfrum , MD;

Stefan Toggweiler , MD;

Giacomo M. Cioffi , MD;

Federico Moccetti , MD;

Francesco Ferraro , MD;

Mehdi Madanchi , MD;

Eleonora Gnan , MD;

Matthias Bossard , MD;

Varis Gjergjizi , MD;

The study aimed to describe the safety and long-term outcomes of patients with coronary chronic total occlusions undergoing percutaneous coronary interventions with the latest generation of drug-coated balloons vs novel drug-eluting stents.

The study aimed to describe the...

02/21/2024

Journal of Invasive Cardiology

AMP 2023

Current Clinical Data on RANGER DCB: RANGER II SFA, COMPARE, and Real-World Experience with ELEGANCE

11/13/2023

Pradeep K. Nair , MD, FACC, FSCAI;

In this video recorded at AMP 2023, Dr. Pradeep Nair discusses his presentation on the clinical data available on the Ranger drug-coated balloon.

In this video recorded at AMP...

11/13/2023

Vascular Disease Management

Original Research

Clinical Performance of a Paclitaxel Drug-Coated Balloon in Real-World Percutaneous Coronary Intervention Practice: The PEARL Registry

06/01/2022

Selina Vlieger , MSc;

Jin M. Cheng , MD, PhD;

Rohit M. Oemrawsingh , MD, PhD;

Auke P.J.D. Weevers , MD;

Jawed Polad , MD;

Ben Gho , MD, PhD;

Martijn Meuwissen , MD, PhD;

Eric Boersma , PhD;

Peter den Heijer , MD, PhD;

Alexander JJ. IJsselmuiden , MD, PhD;

Randomized controlled trials for in-stent restenosis (ISR) and de novo lesions in small-diameter vessels have shown promising results, but data on DCB use in real-world practice are still scarce. The aim of the PEARL (Paclitaxel-Eluting...

Randomized controlled trials for...

06/01/2022

Journal of Invasive Cardiology

Original Contribution

Rationale and Design of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Total Occlusions

06/08/2021

Antonio Micari , MD, PhD;

Francesco Liistro , MD;

Jeffrey J. Popma , MD, FACC, FSCAI;

This is a pilot feasibility study and the objective is to evaluate the safety and effectiveness of the investigational device, IN.PACT 014 drug-coated balloon, compared with standard PTA in patients with CLI with CTOs of BTK arteries.

This is a pilot feasibility...

06/08/2021

Cath Lab Digest

Commentary

The Paclitaxel-Coated Conundrum: A Commentary Article

01/14/2020

Michael Patel , MD;

Robert E. Beasley , MD, FSCAI, FSIR;

Michael Patel, MD, and Robert Beasley, MD discuss drug-eluting stents and drug-coated balloons.

Michael Patel, MD, and Robert...

01/14/2020

Vascular Disease Management

FDA Panel

The Future is Going to Be Drug-Coated or Drug-Eluting. We Need Individual Patient Data to Move Forward.

06/27/2019

Konstantinos Katsanos , MSc, MD, PhD;

VDM talks with Konstantinos Katsanos, MSc, MD, PhD, EBIR, Assistant Professor, Interventional Radiology, School of Medicine, Patras University Hospital, Patras, Greece.

VDM talks with Konstantinos...

06/27/2019

Vascular Disease Management

FDA Panel

My View: Paclitaxel Use in Peripheral Arterial Disease

06/24/2019

Richard R. Heuser , MD, FACC, FACP, FESC, FSCAI;

Dr. Richard Heuser comments on the use of paclitaxel in peripheral arterial disease.

Dr. Richard Heuser comments on...

06/24/2019

Vascular Disease Management

Research in Review

Switching From Docetaxel to Paclitaxel and Bevacizumab Improves PFS in NSCLC

12/08/2016

JCP Editors

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new...

...

12/08/2016

Journal of Clinical Pathways